|
|
QINA FOR HIV &
AIDS
Clinically Proven
Does Qina Cure
AIDS?
Cure as defined by
the medical dictionary:- Restoration of health; recovery from
disease. A method
or course of medical treatment used to restore health. An
agent, such as a drug or remedy that restores health. To effect
a cure or recovery. To heal, to make well, to restore to good
health.
AIDS is not a disease,
but a classification. No one has ever died from AIDS but rather
an AIDS related illness. To be classified as having AIDS,
a person must be tested as being HIV positive as well as having
a CD4 count of less than 200.
If therefore by using Qina and your CD4 count rises above
the 200 level, then you have either been cured from AIDS or
you have been declassified as an AIDS patient, the terminology
is subjective.
Some of the statements
made on this page have definitely ruffled some feathers
mainly
from the medical quarter that emphatically believe
that the only treatment for AIDS is with Anti Retro Virals
(ARV's).
Because we have both clinical evidence and thousands of
testimonials to the contrary we would be doing the public
an injustice
by not presenting Qina as a safe, effective and affordable
treatment of HIV & AIDS.
If you are not aware
of the controversy surrounding HIV / AIDS and ARV's click
here.
There are only two
ways of killing a virus, firstly a vaccine and secondly
the
immune system. There has been over thirty failed attempts
to develop a vaccine and therefore the only logical approach
is to utilize the immune system. It has been proven that
Qina induces morphological alterations of macrophages within
24
hours. Apart from a decrease in tumor necrosis
factor-alpha (TNFalpha) production, an increase
in CD4 &
CD8 counts were observed as well as a reduction in viral
loads.
What does
this mean ?
The key indicators
of a failing immune system is the CD4 count and the ratio
of CD8 to CD4 levels associated with high viral loads. A
patient can still die with a high CD4 count if associated
with a high viral load. The key is to improve the CD4 count
and reduce the viral load to avoid the potential of an opportunistic
infection. In Aids/HIV cases, Qina promotes an increase
in the number of active T and B lymphocytes, as well as
the number of cytokines. Therefore, patients immediately
respond to treatment, with a decrease in the incidence level
of opportunistic diseases, such as pneumonia and other infections.
The viral burden is reduced to very low levels, becoming,
in some cases, almost non-detectable. In addition to the
specific efficacy on the immunologic stimulation against
the infection, Qina provided quality of life to patients
submitted to aggressive ARV therapies. For this reason,
it may be used in association with other traditional treatments,
such as Anti-Retro-Viral's, but reported accounts show
better results prior to ARV intervention.
Results from
the Qina studies - (randomized,
placebo, double blind controlled)
- 70% of Qina patients started with
opportunistic infections. After 6 months this was reduced
to 5%. The control group started with 45% infections which
dropped to 22% after 1 month but then rose again to 35%
after 6 months.
- Only 20% of the Qina patients had
a drop in viral loads less than 90%, while the control group
had a 65% therapeutic failure.
- CD 4 counts rose almost immediately
within the first month and continued to rise after 6 months.
The control group rose within the 1st month but leveled
off between a range of 220 and 350.
- Nausea and vomiting decreased within
the first week and energy levels increased allowing patients
who were bedridden the freedom to take part in active duties.
- Improved appetite and weight gain
in most patients was significant
- In a quarter of
the patients, Qina was used together with
ARV's without significant incidence or side effects. Three
quarters of patients used Qina alone with significant results
especially on their physical well being as well as the improvement
of CD4 and viral loads.
- There
was an overall improvement in the quality of life and all
patients decided unilaterally to continue with the medication
even after the trial had been completed.
The latest
Scientific Study on HAART or Anti Retroviral Treatment
The latest report published
in The Lancet (2006; 368:451-458), shows that HAART does not
reduce mortality rates for people with HIV. Analyzing information
generated since the introduction of HAART, including data from
over 20,000 patients, the study found that: “Virological
response after starting HAART improved over calendar years,
but such improvement has not translated into a decrease in
mortality.”
In other words, antiretroviral drugs are
useful in boosting CD4 counts and decreasing viral loads, but
these arbitrary surrogate markers are useless in determining
clinical outcomes, and the drugs ultimately have had no effect
on prolonging life.
This study can mean one of three things:
1. The toxic virocidal effects of the drugs are not worth taking.
2. There may be other factors besides the virus
3. HIV does not cause AIDS.
When to take
Qina ?
Administration should commence prior to CD4 counts reaching
the 200 level.
:
To be used in conjunction with ARV therapy
If you have abandoned the treatment or do not have access
to ARV's
if you are "beyond
therapeutic effect" and standard medical protocol has failed
or been discontinued.
|
